

Drug treatment for multidrug-resistant *Acinetobacter baumannii* infections.

[Bassetti M](#), [Righi E](#), [Esposito S](#), [Petrosillo N](#), [Nicolini L](#).

Clinica Malattie Infettive, Azienda Ospedaliera Universitaria San Martino, Largo R Benzi 10, 16132 Genova, Italy. matteo.bassetti@hsanmartino.it

Abstract

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) *A. baumannii* is a rapidly emerging pathogen in healthcare settings, where it causes infections that include bacteremia, pneumonia, meningitis, and urinary tract and wound infections. Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to the carbapenems. Other therapeutic options include sulbactam, aminoglycosides, polymyxins and tigecycline. The discovery of new therapies coupled with the development of controlled clinical trial antibiotic testing combinations and the prevention of transmission of MDR *Acinetobacter* infection are essential to face this important hospital problem.

PMID: 19072182 [PubMed - indexed for MEDLINE]